PPARγ agonists promote the resolution of myelofibrosis in preclinical models

I Myelofibrosis (MF) is a non-BCR-ABL myeloproliferative neoplasm associated with poor outcomes. Current treatment has little effect on the natural history of the disease. MF results from complex interactions between (a) the malignant clone, (b) an inflammatory context, and (c) remodeling of the bon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of clinical investigation 2021-06, Vol.131 (11), p.1-16
Hauptverfasser:	Lambert, Juliette, Saliba, Joseph, Calderon, Carolina, Sii-Felice, Karine, Salma, Mohammad, Edmond, Valérie, Alvarez, Jean-Claude, Delord, Marc, Marty, Caroline, Plo, Isabelle, Kiladjian, Jean-Jacques, Soler, Eric, Vainchenker, William, Villeval, Jean-Luc, Rousselot, Philippe, Prost, Stéphane
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Anemia Animal models BCR-ABL protein Biomedical research Bone marrow Bone remodeling Cell growth Cloning Disease Fusion protein Hemoglobin Hyperplasia Inflammation Leukemia Medical prognosis Microenvironments Myelofibrosis Myeloproliferation Pathogenesis Spleen Stem cells Stroma Therapeutic targets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!